4.6 Article

Pro-inflammatory allogeneic DCs promote activation of bystander immune cells and thereby license antigen-specific T-cell responses

Journal

ONCOIMMUNOLOGY
Volume 7, Issue 3, Pages -

Publisher

TAYLOR & FRANCIS INC
DOI: 10.1080/2162402X.2017.1395126

Keywords

Allogeneic dendritic cells; cell-based immunotherapy; innate immune cells; cell activation

Funding

  1. Swedish Cancer Society [CAN 2013/373, CAN 2016/318]
  2. Swedish Children Cancer Foundation [PR2015-0049]
  3. Swedish Research Council [2015-03688]
  4. Immunicum AB
  5. Swedish Research Council [2015-03688] Funding Source: Swedish Research Council

Ask authors/readers for more resources

Accumulating evidence support an important role for endogenous bystander dendritic cells (DCs) in the efficiency of autologous patient-derived DC-vaccines, as bystander DCs take up material from vaccine-DCs, migrate to draining lymph node and initiate antitumor T-cell responses. We examined the possibility of using allogeneic DCs as vaccine-DCs to activate bystander immune cells and promote antigen-specific T-cell responses. We demonstrate that human DCs matured with polyI:C, R848 and IFN- (denoted COMBIG) in combination with an infection-enhanced adenovirus vector (denoted Ad5M) exhibit a pro-inflammatory state. COMBIG/Ad5M-matured allogeneic DCs (alloDCs) efficiently activated T-cells and NK-cells in allogeneic co-culture experiments. The secretion of immunostimulatory factors during the co-culture promoted the maturation of bystander-DCs, which efficiently cross-presented a model-antigen to activate antigen-specific CD8+ T-cells in vitro. We propose that alloDCs, in combination with Ad5M as loading vehicle, may be a cost-effective and logistically simplified DC vaccination strategy to induce anti-tumor immune responses in cancer patients.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Hematology

TARP is an immunotherapeutic target in acute myeloid leukemia expressed in the leukemic stem cell compartment

Barbara Depreter, Karin E. Weening, Karl Vandepoele, Magnus Essand, Barbara De Moerloose, Maria Themeli, Jacqueline Cloos, Diana Hanekamp, Ine Moors, Inge D'hont, Barbara Denys, Anne Uyttebroeck, An Van Damme, Laurence Dedeken, Sylvia Snauwaert, Glenn Goetgeluk, Stijn De Munter, Tessa Kerre, Bart Vandekerckhove, Tim Lammens, Jan Philippe

HAEMATOLOGICA (2020)

Article Cell Biology

Characterization of virus-mediated immunogenic cancer cell death and the consequences for oncolytic virus-based immunotherapy of cancer

Jing Ma, Mohanraj Ramachandran, Chuan Jin, Clara Quijano-Rubio, Miika Martikainen, Di Yu, Magnus Essand

CELL DEATH & DISEASE (2020)

Article Immunology

Astrocytes have the capacity to act as antigen-presenting cells in the Parkinson's disease brain

Jinar Rostami, Grammatiki Fotaki, Julien Sirois, Ropafadzo Mzezewa, Joakim Bergstrom, Magnus Essand, Luke Healy, Anna Erlandsson

JOURNAL OF NEUROINFLAMMATION (2020)

Article Chemistry, Multidisciplinary

Development of a New Hyaluronic Acid Based Redox-Responsive Nanohydrogel for the Encapsulation of Oncolytic Viruses for Cancer Immunotherapy

Siyuan Deng, Alessandra Iscaro, Giorgia Zambito, Yimin Mijiti, Marco Minicucci, Magnus Essand, Clemens Lowik, Munitta Muthana, Roberta Censi, Laura Mezzanotte, Piera Di Martino

Summary: A redox responsive nanohydrogel based on hyaluronic acid was developed as a delivery system for oncolytic viruses, showing rapid degradation in a reductive environment and good oncolytic activity. Due to its hydrophilic and porous nature, the nanohydrogel is considered a promising carrier for viral drugs.

NANOMATERIALS (2021)

Article Cardiac & Cardiovascular Systems

Perivascular Macrophages Regulate Blood Flow Following Tissue Damage

Evelina Vagesjo, Kristel Parv, David Ahl, Cedric Seignez, Carmen Herrera Hidalgo, Antoine Giraud, Catarina Leite, Olle Korsgren, Hakan Wallen, Greta Juusola, Harri H. Hakovirta, Helene Rundqvist, Magnus Essand, Lena Holm, Randall S. Johnson, Charlotte Thalin, Petra Korpisalo, Gustaf Christoffersson, Mia Phillipson

Summary: This study reveals a novel role of macrophages in regulating blood flow by releasing iNOS in ischemic muscles to improve tissue perfusion and repair. Depletion of iNOS in macrophages compromised blood flow regulation and exacerbated ischemic damage in the muscles.

CIRCULATION RESEARCH (2021)

Article Multidisciplinary Sciences

Agonistic CD40 therapy induces tertiary lymphoid structures but impairs responses to checkpoint blockade in glioma

Luuk van Hooren, Alessandra Vaccaro, Mohanraj Ramachandran, Konstantinos Vazaios, Sylwia Libard, Tiarne van de Walle, Maria Georganaki, Hua Huang, Ilkka Pietilae, Joey Lau, Maria H. Ulvmar, Mikael C. I. Karlsson, Maria Zetterling, Sara M. Mangsbo, Asgeir S. Jakola, Thomas Olsson Bontell, Anja Smits, Magnus Essand, Anna Dimberg

Summary: This study demonstrates that the use of immunostimulatory CD40 antibodies in glioma models promotes the formation of tertiary lymphoid structures but does not improve survival and impairs the response to immune checkpoint blockade.

NATURE COMMUNICATIONS (2021)

Review Immunology

Tertiary Lymphoid Structures in the Central Nervous System: Implications for Glioblastoma

Tiarne van de Walle, Alessandra Vaccaro, Mohanraj Ramachandran, Ilkka Pietila, Magnus Essand, Anna Dimberg

Summary: Glioblastoma is an aggressive brain tumor with a low prevalence of tumor-reactive T cells, and recent data suggest that naive T cells may be activated within brain tumor-associated tertiary lymphoid structures. Promoting tertiary lymphoid structures could enhance priming of tumor antigen-targeted T cells and sensitize glioblastomas to cancer immunotherapy.

FRONTIERS IN IMMUNOLOGY (2021)

Article Oncology

IFN-I-tolerant oncolytic Semliki Forest virus in combination with anti-PD1 enhances T cell response against mouse glioma

Miika Martikainen, Mohanraj Ramachandran, Roberta Lugano, Jing Ma, Minttu-Maria Martikainen, Anna Dimberg, Di Yu, Andres Merits, Magnus Essand

Summary: The study constructed an IFN-I-resistant SFV-AM6 virus that induced immunogenic apoptosis in GL261 cells and showed therapeutic potency against glioma. Additionally, combination therapy with SFV-AM6-124T and antiPD1 immunotherapy promoted an inflammatory response and increased tumor-reactive CD8(+) cells in the GL261 glioma model.

MOLECULAR THERAPY-ONCOLYTICS (2021)

Article Nanoscience & Nanotechnology

Targeting circulating monocytes with CCL2-loaded liposomes armed with an oncolytic adenovirus

Alessandra Iscaro, Christian Jones, Neil Forbes, Amina Mughal, Faith Nutter Howard, Haider Al Janabi, Secil Demiral, Yvonne Perrie, Magnus Essand, Aleksandra Weglarz, Luis J. Cruz, Claire E. Lewis, Munitta Muthana

Summary: This study demonstrates that encapsulating oncolytic adenovirus into CCL2-coated liposomes can effectively target tumors by recruiting circulating monocytes expressing CCR2. The nanomedicine approach significantly reduces tumor size and metastasis, providing a potential strategy for treating inaccessible tumors.

NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE (2022)

Article Biotechnology & Applied Microbiology

Ixovex-1, a novel oncolytic E1B-mutated adenovirus

Mohiemen Anwar, Maja-Louise Arendt, Mohanraj Ramachandran, Anette Carlsson, Magnus Essand, Goran Akusjarvi, Ghasan Alusi, Daniel Oberg

Summary: This research describes a novel oncolytic adenovirus, Ixovex-1, which selectively replicates within cancer cells by modulating the level of expression of different E1B mRNA isoforms. The study demonstrates the characteristics and anti-tumor efficacy of Ixovex-1 in both in vitro and in vivo experiments, showing its superiority compared to other viruses with multiple deletions.

CANCER GENE THERAPY (2022)

Article Engineering, Biomedical

CAR T cells expressing a bacterial virulence factor trigger potent bystander antitumour responses in solid cancers

Chuan Jin, Jing Ma, Mohanraj Ramachandran, Di Yu, Magnus Essand

Summary: CAR T cells expressing NAP from Helicobacter pylori can trigger endogenous bystander T-cell responses against solid cancers, improving tumor growth and survival rates.

NATURE BIOMEDICAL ENGINEERING (2022)

Article Oncology

Intratumoral administration of pro-inflammatory allogeneic dendritic cells improved the anti-turnor response of systemic anti-CTLA-4 treatment via unleashing a T cell-dependent response

Chuan Jin, Arwa Ali, Alexandros Iskantar, Grammatiki Fotaki, Hai Wang, Magnus Essand, Alex Karlsson-Parra, Di Yu

Summary: This study demonstrates that a combination treatment involving intratumoral administration of pro-inflammatory allogeneic dendritic cells (AlloDCs) and systemic treatment with alpha CTLA-4 can significantly enhance the anti-tumor efficacy compared to alpha CTLA-4 monotherapy. The combination treatment leads to an immune-inflamed tumor microenvironment characterized by increased infiltration of activated endogenous antigen-presenting dendritic cells and CD8(+) T cells with a tissue-resident memory phenotype. This study highlights the potential of this combination therapy for improving the response to immune checkpoint inhibitors.

ONCOIMMUNOLOGY (2022)

Article Oncology

Tumor endothelial cell up-regulation of IDO1 is an immunosuppressive feed-back mechanism that reduces the response to CD40-stimulating immunotherapy

Maria Georganaki, Mohanraj Ramachandran, Sander Tuit, Nicolas Gonzalo Nunez, Alexandros Karampatzakis, Grammatiki Fotaki, Luuk van Hooren, Hua Huang, Roberta Lugano, Thomas Ulas, Aura Kaunisto, Eric C. Holland, Peter Ellmark, Sara M. Mangsbo, Joachim Schultze, Magnus Essand, Sonia Tugues, Anna Dimberg

ONCOIMMUNOLOGY (2020)

No Data Available